BPC-157 and the healing-peptide category, honestly.

Last week we covered FDA-approved GLP-1s. This week, the middle tier — the "healing peptides" that get heavy promotion in functional medicine clinics, biohacker podcasts, and longevity influencer accounts.

The honest summary up front: BPC-157, TB-500, CJC-1295, Ipamorelin, Epitalon, MOTS-c, and similar peptides have interesting preclinical data and limited human research. None are FDA-approved for any indication. They're sold under "for research use, not for human consumption" labels and used for human consumption anyway.

This letter is the audit. We're not going to recommend brands, dosing protocols, or suppliers — we'll explain what we know about the molecules and let you make your own decisions.

BPC-157 (Body Protection Compound)

What it is: A 15-amino-acid peptide derived from a sequence found in human gastric juice.

Animal data: Robust. Healing of tendons, ligaments, gastric ulcers, and various injury models in rats. Hundreds of papers, mostly from a single research group in Zagreb, Croatia.

Human data: Almost none. A few small case series with limited methodological rigor. No randomized controlled trials in humans for any indication.

Use claims: Tendon healing, gut healing, accelerated injury recovery, anti-inflammatory effects.

Risk profile: Reasonable in the limited human reports. No serious adverse events documented. Long-term safety data essentially absent.

Legal status: Not FDA-approved. WADA-prohibited for athletes since 2022. Sold via "research compound" channels.

Honest verdict: If you have a stubborn tendon injury that conventional medicine hasn't helped, this is in the category some people try. The downside risk appears low; the upside benefit is unproven in humans. If you go this route, know that you're in the experimental tier and dose accordingly.

TB-500 / Thymosin Beta-4

What it is: A peptide derived from the protein thymosin beta-4.

Animal data: Decent. Tissue repair, angiogenesis (new blood vessel growth) in injury models.

Human data: Some Phase 1 and 2 trials for specific indications (dry eye disease, dermal ulcers, heart attack recovery). RegeneRx is the pharma company developing it. Most trials have been small.

Use claims: Similar to BPC-157 — accelerated healing, tissue repair.

Risk profile: No major safety concerns in published trials. Long-term human use data limited.

Honest verdict: Slightly more human research than BPC-157, mostly still preliminary. Same category — interesting molecule, premature for confident recommendation.

CJC-1295 + Ipamorelin (growth hormone secretagogues)

What they are: Peptides that stimulate the pituitary to release more growth hormone. Often used together.

Effect: Modest increase in endogenous GH and IGF-1. Marketed for "anti-aging," fat loss, muscle gain, sleep improvement.

The catch nobody promotes: elevated GH and IGF-1 in adults are associated with several cancers in observational studies. The "raise GH for longevity" thesis is increasingly out of favor; the modern longevity literature suggests LOWER GH/IGF-1 axes in adulthood correlate with longer lifespan (see the centenarian dwarfism research on Laron syndrome).

Honest verdict: The mechanism (raise GH) is increasingly suspect for longevity purposes. The body composition effect is modest. The cancer-promotion risk is real but small. We do not recommend this category for healthy adults.

Epitalon

What it is: Synthetic peptide based on epithalamin, originally isolated from the pineal gland.

Data: Almost all from a single Russian research lab. Animal data showing extended lifespan, telomere lengthening, melatonin normalization. Some small Russian human trials on geriatric populations.

Western replication: Essentially zero.

Honest verdict: The animal data is interesting; the human evidence is thin and not independently replicated. The longevity claims are mostly extrapolation from rodent studies. Pass.

MOTS-c

What it is: A short mitochondrial-derived peptide.

Data: Interesting basic-science papers on mitochondrial function and metabolic regulation. Almost no human trial data.

Use claims: Metabolic health, exercise performance, healthspan.

Honest verdict: Most speculative of the category. The biology is real and interesting. The clinical application in humans is essentially unproven. Premature.

Why we're not writing a buying guide

Three reasons:

1. Supply chain unknown. "Research peptides" are typically synthesized in unregulated facilities (often in China). Quality varies dramatically. Purity testing is rare. Some product is fine; some is contaminated; some is not what the label says.

2. Dosing protocols come from internet forums. There's no clinical dosing guidance because there's no clinical use. The "5 days on, 2 days off" protocols you see are extrapolations from animal models. They may be right; they may not.

3. The downside isn't necessarily catastrophic, but it isn't characterized. Most people who try these don't have problems. We don't know what happens to the small percentage who do, because there's no surveillance system tracking adverse events in "research peptide" users.

The honest position: if you decide to experiment in this category, you're doing so in an unregulated way, and you should accept that responsibility. We're not going to direct you to suppliers because we can't quality-check them, and we're not going to publish protocols because we don't have outcome data to back them up.

What we recommend instead

If you came to this letter wanting a healing/recovery edge:

• Sleep architecture optimization (letter #14). Single biggest healing intervention. Free.
• Protein floor at 0.8g/lb (letter #2). Tissue repair requires substrate.
• Resistance training (letter #12). Increases tissue regeneration capacity.
• Limit alcohol (letter #13). Alcohol suppresses GH and IGF-1, which suppresses healing.
• HRT or TRT if clinically indicated (letters #1 and #8). The endogenous hormone you already have is probably the highest-leverage hormone you can touch.

These five interventions outperform the entire research-peptide category in evidence quality and dollars-per-effect.

Next week: microbiome reset at 50 — what the research actually says and what is mostly hype.

Alexander After Forty Feel Reader-funded. Research-led. No supplement-brand sponsorships.

2026 Updates & Context

Key developments since earlier guidance: evolving data on GLP-1 + hormone interactions, refined risk stratification for HRT/TRT, new non-hormonal options, and better tools for body composition tracking. The fundamentals (individualization, resistance training, protein adequacy, sleep) remain the highest-leverage inputs.

Last framework refresh: 2026-06-01

Practical Tools (2026)

• Magnesium glycinate — high-ROI for sleep quality and recovery in midlife.
• Adjustable resistance equipment — for consistent training without gym dependency.

Affiliate disclosure: Links above are Amazon Associates examples. Purchases may earn a commission at no extra cost. We only recommend tools discussed in the research.

2026 Decision Framework

Core questions to answer before acting:

• What is my personal risk/benefit profile based on age, timing, labs, and symptoms?
• Which levers (hormones, training, nutrition, sleep, stress) should I pull first?
• What is my 3-month, 12-month, and 5-year plan for reassessment?

This is synthesis of current evidence — not personalized medical advice.

Launch Campaign Assets (automation)